Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma

Published:2018-02-01 Issue:3 Volume:67 Page:1132-1149
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Bouattour Mohamed¹^ORCID,Raymond Eric²,Qin Shukui³,Cheng Ann-Lii⁴,Stammberger Uz⁵,Locatelli Giuseppe⁵,Faivre Sandrine⁶

Affiliation:

1. Digestive Oncology Department; Beaujon University Hospital; Clichy France

2. Oncology Unit; Groupe Hospitalier Paris Saint Joseph; Paris France

3. Medical Oncology Department; Nanjing Bayi Hospital; Nanjing China

4. National Taiwan University Hospital; Taipei Taiwan ROC

5. Merck KGaA; Darmstadt Germany

6. Medical Oncology Department; Beaujon University Hospital; Clichy France

Publisher

Wiley

Subject

Hepatology

Reference97 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis;El-Serag;Gastroenterology,2007

3. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients;Greten;Br J Cancer,2005

4. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled;Matsuda;Med Mol Morphol,2011

5. US Food and Drug Administration Regorafenib https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555548.htm 2017

Cited by 186 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. WNT/β-catenin signaling in hepatocellular carcinoma: The aberrant activation, pathogenic roles, and therapeutic opportunities;Genes & Diseases;2024-03

2. OTUB1 accelerates hepatocellular carcinoma by stabilizing RACK1 via its non-canonical ubiquitination;Cellular Oncology;2024-02-05

3. Design, Synthesis, and Biological Evaluation of 2-Substituted Aniline Pyrimidine Derivatives as Potent Dual Mer/c-Met Inhibitors;Molecules;2024-01-18

4. A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma;JHEP Reports;2024-01

5. Discovery of potent and selective c-Met inhibitors for MET-amplified hepatocellular carcinoma treatment;European Journal of Medicinal Chemistry;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3